studies on retatrutide Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial Retatrutide 25mg – Research Peptide

A 2022 study showed that participants who discontinued GLP-1 agonist treatment gained most of their weight back within 1 year

When activated, this receptor triggers several responses throughout the body

This suggests that GLP-1 RAs may directly influence these areas, thereby affecting emotional and behavioral states [81]

This doctor-led model helps ensure safe, appropriate treatment choices for patients who may still be on GLP-1 medications or have medical conditions related to their weight-loss journey. Our practice offers a full suite of non-invasive skin rejuvenation services, including INDIBA Radiofrequency, microneedling, and other technologies designed to address fine lines, sun damage, and skin laxity